Vaccinex

08/18/2026

Attending the Antibody Therapeutics Xchange in San Francisco and curious about our ActivMab Technology? Let’s connect and discuss how our transmembrane protein technology can help your discovery projects. Discovery

07/13/2026

Vaccinex is advancing pepinemab into Phase 2b clinical trials, exploring a new direction in Alzheimer’s treatment.
Unlike amyloid-targeting therapies, pepinemab focuses on astrocyte-driven neuroinflammation—an upstream mechanism linked to synaptic damage and cognitive decline.
This pathway-based approach could complement existing treatments and reshape how neurodegenerative diseases are addressed.

Pepinemab Alzheimer’s drug trial data showed no brain-swelling risk at AAIC 2026, as Vaccinex presented SIGNAL-AD biomarker findings and announced plans for a Phase 2b randomized trial of its SEMA4D antibody — a neuroinflammation-targeted approach that works differently from approved amyloid

07/07/2026

Vaccinex will be at in London, UK (July 12–15, 2026).
Join us for our presentation on Monday, July 13 (9:00–10:30 AM) in the Featured Research Session “Alzheimer’s Therapy: Mechanisms Beyond Amyloid.”
We’ll be discussing biomarkers of reactive glia and neuroinflammation associated with cognitive decline and Alzheimer’s disease progression. Pepinemab is a novel approach designed to interrupt these events in early-stage AD.
Stop by to learn more—we look forward to connecting!

06/30/2026

Still time to set up your 1:1 meeting with Vaccinex at .

Heading to ?
Vaccinex is advancing development of pepinemab, an anti-SEMA4D antibody, in an enlarged Phase 2b clinical trial for the treatment of Alzheimer’s disease.
Evidence suggests that Pepinemab:
• Blocks reactive gliosis contributing to neuroinflammation
• Preserves vascular integrity in brain
• Downregulates expression of AD-related proteins
Clinical and multiomics data support that treatment early in disease has favorable effects on biomarkers and appears to slow cognitive decline.
We welcome the opportunity to connect at AAIC.
Schedule a 1:1 meeting: [email protected]

06/03/2026

Attending BIO International and curious about our ActivMab Technology? Let’s connect through the BIO Partnering system!

We welcome the opportunity to discuss how our transmembrane protein technology can help your discovery projects.

05/21/2026

Research featuring Vaccinex’s anti-SEMA4D antibody pepinemab was highlighted in a top 10% most-viewed Alzheimer’s & Dementia paper of 2024, published on behalf of the . The publication highlights emerging advances in neuroimmunity, including SEMA4D signaling, glial biology, and neuroinflammatory mechanisms in Alzheimer’s disease.

The recognition reflects growing momentum behind targeting SEMA4D-driven neuroinflammation and glial dysfunction in Alzheimer’s disease.

We look forward to joining the conversation at .

Read the full article here:
https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/ALZ.14291?utm_campaign=B2CJNL_MIS_1693050_2026_Top_Viewed_Authors_EM1_T&utm_medium=email&utm_source=sfmc

05/11/2026

Join us today at 12:10 PM EST as Ernest Smith, PhD from Vaccinex presents our ActivMAb® technology at the PEGS Boston Summit.
The session will highlight antibody discovery for complex membrane antigens and its potential in advancing cancer therapies.
If you’re attending PEGS, we’d love to connect- stop by poster A117: Antibody Discovery for Complex Membrane Antigens!

04/27/2026

Heading to ?
Vaccinex is advancing development of pepinemab, an anti-SEMA4D antibody, in an enlarged Phase 2b clinical trial for the treatment of Alzheimer’s disease.
Evidence suggests that Pepinemab:
• Blocks reactive gliosis contributing to neuroinflammation
• Preserves vascular integrity in brain
• Downregulates expression of AD-related proteins
Clinical and multiomics data support that treatment early in disease has favorable effects on biomarkers and appears to slow cognitive decline.
We welcome the opportunity to connect at AAIC.
Schedule a 1:1 meeting: [email protected]